<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="53462">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02410200</url>
  </required_header>
  <id_info>
    <org_study_id>109MS202</org_study_id>
    <secondary_id>2014-005003-24</secondary_id>
    <nct_id>NCT02410200</nct_id>
  </id_info>
  <brief_title>Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS</brief_title>
  <acronym>FOCUS</acronym>
  <official_title>Open-Label, Multicenter, Multiple-Dose Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis Aged 10 to 17 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the effect of BG00012 (dimethyl fumarate)
      on brain magnetic resonance imaging (MRI) lesions in pediatric subjects with
      Relapsing-Remitting Multiple Sclerosis (RRMS). The secondary objectives of this study are as
      follows: To characterize the pharmacokinetics (PK) of BG00012 in pediatric subjects with
      RRMS; To evaluate the safety and tolerability of BG00012 in pediatric subjects with RRMS.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the number of new or newly enlarging T2 hyperintense lesions on brain MRI scans from the Baseline Period to On-Treatment Assessment Period</measure>
    <time_frame>Week -8 to Week 24</time_frame>
    <description>the Baseline Period is from Week -8 to Day 0 and the On-Treatment Assessment Period is from Week 16 to Week 24</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>maximum observed plasma concentration (Cmax)</measure>
    <time_frame>Up to Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to reach maximum observed plasma concentration (Tmax)</measure>
    <time_frame>Up to Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>apparent clearance (CL/F)</measure>
    <time_frame>Up to Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>apparent volume of distribution (V/F)</measure>
    <time_frame>Up to Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>elimination half-life (t½)</measure>
    <time_frame>Up to Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>area under the concentration-time curve from time 0 to infinity (AUC0-inf)</measure>
    <time_frame>Up to Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants that experience treatment-emergent Adverse Events (AEs) and Serious Adverse events (SAEs)</measure>
    <time_frame>Up to Week 28</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Multiple Sclerosis, Relapsing-Remitting</condition>
  <arm_group>
    <arm_group_label>dimethyl fumarate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 120 mg capsule(s) taken orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dimethyl fumarate</intervention_name>
    <description>administered orally</description>
    <arm_group_label>dimethyl fumarate</arm_group_label>
    <other_name>BG00012</other_name>
    <other_name>DMF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Ability of parents or legal guardians to understand the purpose and risks of the
             study and provide signed and dated informed consent and authorization to use
             protected health information in accordance with national and local subject privacy
             regulations. Subjects will provide assent in addition to the parent or legal
             guardian, as appropriate, as per local regulations.

          -  Must have a body weight of ≥30 kg at Screening and Day 1.

          -  Must have a diagnosis of RRMS according to McDonald criteria for MS (2010) [Polman
             2011] and International Pediatric Multiple Sclerosis Study Group criteria for
             pediatric MS (2013) [Krupp 2013].

        Key Exclusion Criteria:

          -  Primary progressive, secondary progressive, or progressive relapsing MS (as defined
             by [Lublin and Reingold 1996]). These conditions require the presence of continuous
             clinical disease worsening over a period of at least 3 months. Subjects with these
             conditions may also have superimposed relapses but are distinguished from
             relapsing-remitting subjects by the lack of clinically stable periods or clinical
             improvement.

          -  Disorders mimicking MS, such as other demyelinating disorders (e.g., acute
             disseminated encephalomyelitis), systemic autoimmune disorders (e.g., Sjögren
             disease, lupus erythematosus, and neuromyelitis optica), metabolic disorders (e.g.,
             dystrophies), and infectious disorders.

          -  History of severe allergic or anaphylactic reactions or known drug hypersensitivity
             to dimethyl fumarate (DMF) or fumaric acid esters.

        NOTE: Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Bernadino</city>
        <state>California</state>
        <zip>92408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gent</city>
        <zip>B-9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>B-1113</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hradec kralove</city>
        <zip>500 05</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Munchen</city>
        <state>Bayern</state>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gottingen</city>
        <state>Niedersachsen</state>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dasman</city>
        <state>Kuwait City</state>
        <zip>15462</zip>
        <country>Kuwait</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Riga</city>
        <zip>LV-1004</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beirut</city>
        <zip>1107 2020</zip>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznan</city>
        <zip>60-355</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kocaeli</city>
        <zip>41380</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Samsun</city>
        <zip>55139</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Kuwait</country>
    <country>Latvia</country>
    <country>Lebanon</country>
    <country>Poland</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 29, 2016</lastchanged_date>
  <firstreceived_date>April 2, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatrics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dimethyl Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
